There’s officially a new and fierce competitor for Novo Nordisk’s Wegovy (semaglutide) when it comes to weight loss. On Wednesday, the Food and Drug Administration approved the drug tirzepatide, developed by Eli Lilly, as a treatment for obesity. The weekly injectable drug will be sold under the brand name Zepbound.
There’s officially a new and fierce competitor for Novo Nordisk’s Wegovy (semaglutide) when it comes to weight loss. On Wednesday, the Food and Drug Administration approved the drug tirzepatide, developed by Eli Lilly, as a treatment for obesity. The weekly injectable drug will be sold under the brand name Zepbound.Read more… Read More obesity, eli lilly and company, anti obesity medication, health medical pharma, semaglutide, glucagon like peptide 1, glucagon like peptide 1 receptor agonist, john sharretts, weight loss, tirzepatide, novo nordisk, diabetes, peptide hormones, cagrilintidesemaglutide, eli lilly, hospitality recreation Gizmodo
